[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562737":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":29,"responsibleParty":45,"collaborators":10,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":49,"sex":55,"minAge":56,"maxAge":10,"enrollmentInfo":57,"targetDuration":10,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":10,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Centre Hospitalier Intercommunal Aix-Pertuis","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Interventional - blood collection",null,"HLA-DR dosage, at the time of inclusion and once a week then",[13],"Diagnostic Test: Blood collection",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":10},"DIAGNOSTIC_TEST","Blood collection",[9],[20],{"name":21,"affiliation":5,"role":22},"Laurent LEFEBVRE, MD","PRINCIPAL_INVESTIGATOR",[24],{"name":21,"role":25,"phone":26,"phoneExt":27,"email":28},"CONTACT","0442335650","+33","llefebvre@ch-aix.fr",[30],{"facility":5,"status":31,"city":32,"state":10,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"RECRUITING","Aix-en-Provence","13100","France","FR",{"type":37,"coordinates":38},"Point",[39,40],5.44973,43.5283,{"lat":40,"lon":39},[43],{"name":44,"role":25,"phone":26,"phoneExt":27,"email":28},"Laurent LEFEBVRE",{"type":22,"investigatorFullName":44,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Principal investigator","100562737","immunity-markers-in-intensive-care-patients-and-ventilator-associated-pneumonia-100562737",false,"NCT06607055","Immunity Markers in Intensive Care Patients and Ventilator-associated Pneumonia","Monitoring of Immunity Markers in Intensive Care Patients and Link with Recurrence and Relapse of Ventilator-associated Pneumonia","IMMUNAIX","Inclusion Criteria:\n\n* Patient over 18 years old\n* Patient admitted in the Intensive Care Unit of the CHIAP\n* Patient under mechanical ventilation\n* Patient with infectious pneumonia\n* Informed Consent Form (ICF) obtained from the patient or emergency ICF obtained from close relatives\n* Patient beneficiary of French social security, whatever the regime\n\nExclusion Criteria:\n\n* Patient under 18 years old\n* Patient with severe neutropenia (neutrophils \\\u003C 0.5 G\u002FL)\n* Patient under immunosuppressive treatment\n* Use of corticosteroids (intravenous or oral) prior to ICU admission\n* Use of therapeutic antibodies\n* Onco-hematological disease (e.g. lymphoma, leukemia...) under treatment or treated in the 5 years prior to inclusion\n* End of chemotherapy 6 months prior to inclusion\n* Patients with innate or acquired immune deficiency (e.g., severe combined immunodeficiency, HIV or AIDS, at any stage)\n* Patients with a decision to limit or discontinue active therapies, at the time of inclusion\n* Patients with an estimated ICU stay of less than 48 hours\n* Participation in an interventional study\n* Patient deprived of their liberty\n* Patient under tutorship or curatorship\n* Pregnant or breastfeeding woman","ALL","18 Years",{"count":58,"type":59},40,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to show the direct correlation between the occurrence of recurrence of VAP and postagressive immunoparalysis, monitored by HLA-DR rate below litterature-acknowledged threshold, in a well conducted antibiotherapy context, in patient admitted in the Intensive Care Unit.\n\nThe main questions it aims to answer are:\n\n* evaluation of the association between death and persistence of immunoplegia using HLA-DR monitoring\n* search an association between immunoplegia depth and severity of the initial state of shock\n* search an association between immunoplegia depth and viral reactivation\n* compare association of immunoplegia duration and HLA-DR nadir and VAP occurrence Blood samples will be taken from participants to HLA-DR dosage, at the time of inclusion and once a week then.",[63],"Pneumonia, Ventilator-Associated","2024-09-18",{"date":66,"type":67},"2024-09-23","ACTUAL",{"date":69,"type":67},"2023-10-04",{"date":71,"type":59},"2025-09",{"name":5,"class":6},1]